NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company’s product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer’s disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
तुलना करने के लिए मीट्रिक्स | NXTC | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधNXTCपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −0.8x | −2.7x | −0.5x | |
PEG अनुपात | −0.15 | 0.07 | 0.00 | |
क़ीमत/बुक | 1.9x | 2.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 109.3x | 3.3x | |
अपसाइड (विश्लेषक लक्ष्य) | 39.3% | 183.5% | 45.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | 13.9% | 4.9% | अनलॉक करें |